Twenty-seven patients with severe alopecia areata were treated with dapsone. The results of a mean treatment duration of 10 ± 0-5 months are reported, and compared with the results of long-term topical immunotherapy obtained previously at the same institute. The efficacy of dapsone proved to be markedly inferior to that of topical immunotherapy. The percentage of patients showing regrowth of hair during treatment with dapsone was comparable with the occurrence of spontaneous regrowth of hair reported in the literature.
Alopecia areata (AA) is a disorder of unknown cause, cardiopulmonary disease were excluded from treatt although evidence for an autoimmune aetiology conment with dapsone. Table 1 summarizes the compositinues to mount.1 Various therapies have been reported tion of the two treatment groups. Eleven patients in the to be effective: photochemotherapy,2 topical and sysdapsone treatment group had been treated previously temic corticosteroids,3,4 topical and oral cyclosporin A, 5, 6 with topical immunotherapy. In eight of these patients, topical and oral minoxidil,7'8 and isoprinosine.9 None of topical immunotherapy had been successful initially, these treatments, however, has produced a substantial regrowth of hair in the majority of patients. During the last decade, controlled studies have shown conclusively that the treatment of AA by topical immunotherapy using the contact allergen diphenylcyclopropenone (DCP) is effective. 10, 11 Disadvantages of topical immunotherapy are that it requires close supervision, and the treatment is time-consuming for the patients and medical staff.
In 1990 Knauber and Zaun12 reported that treat ment of AA with dapsone was as effective as topical immunotherapy. However, no consensus has been reached on the value of dapsone for patients with
Â
A. The purpose of the present study was to analyse the effectiveness of dapsone in AA, and to compare the results with the response to topical immunotherapy obtained at the Nijmegen Institute.10,14
Methods
Between January 1992 and August 1993, 27 patients with severe AA were treated with dapsone. Between March 1986 and October 19 8 9, a group of 13 9 patients with severe AA had been treated with DCP at the Nijmegen Institute.10 Informed consent was obtained from all patients.
Included in both groups were patients suffering from severe AA. Pregnant women and those wishing to become pregnant were excluded. Patients with but a relapse had occurred during prolonged treatment. The details of patients treated with DCP have been reported previously. 10, 14 Dapsone was started at a daily dosage of 100 mg. If side-effects such as nausea, headache, sleep disturb ance, anaemia or methaemoglobinaemia occurred, the dosage was reduced to 50 mg daily, or the drug was stopped. This dosage was continued until cosmetically acceptable hair growth had appeared. The dosage was then slowly reduced to the minimum effective level. If, after 12 months, no hair growth had occurred, therapy was stopped. Before treatment, we checked the full blood count, and performed renal and hepatic function tests. These parameters, and the methaemoglobin level, were monitored during treatment. Topical immu notherapy was carried out according to standardized procedures. 10, 14 Hair regrowth was recorded as follows: if some regrowth of hair occurred the response was designated as 'hair growth', and if the regrowth was complete the response was recorded as 'complete hair growth'.
Results
Data on hair growth during treatment with dapsone are summarized in Tables 2-4 . Of the seven patients with the patchy type of AA, four showed complete regrowth. Fourteen patients in the dapsone-treated group showed sporadic hair growth on the scalp. Of these 14 patients, eight also noticed sparse hair growth all over the body, which subsequently disappeared. In the totalis/univer salis group, 10 patients showed some hair growth, but only two had complete regrowth. In these two patients the hair growth appeared after 1 and 5 months, and therapy was stopped at 10 and 8 months, respectively, because of headache and fatigue, it is notable that the hair growth was unaffected by discontinuation of dapsone. Table 4 summarizes the duration of the DCP and dapsone treatment phases. It can be seen that improve ment during dapsone therapy initially occurred after 2-2 db 0-6 months in 14 patients, and that cosmetically acceptable regrowth was seen after 10 ± 0-7 months in six patients. No significant correlation was observed between the dosage of dapsone and its clinical efficacy. Notably, those patients in the totalis/universalis group who had regrowth of hair received dapsone 50 mg daily. Topical immunotherapy with DCP was continued for a year in 139 patients.10,14 If, after this duration of therapy, cosmetically acceptable regrowth had not occurred, treatment was stopped. Data on hair regrowth during immunotherapy are presented in Tables 3 and 4 . Of the 44 patients with the patchy type of AA, 34 had complete hair regrowth, and of the 85 patients with subtotalis/totalis type of AA, 33 had complete hair regrowth. As topical immunotherapy is initiated on one side of the scalp, a unilateral response can be interpreted as a therapeutic success, and a bilateral response as spontaneous regrowth. Of the 139 patients, 107 had a unilateral response and none showed a bilateral response.
A period of topical immunotherapy of approximately 3 months was required before signs of regrowth occurred, and at least 6 months for complete regrowth. A comparison of the effectiveness of dapsone with topical immunotherapy revealed that complete regrowth occurred in 22 and 50% of the patients, respectively. It can be concluded that topical immu notherapy is significantly more effective than dapsone (Fisher's exact test: P ^ 0-006).
Side-effects are listed in Table 5 . In two of 2 7 patients treated with dapsone (7%), the dose was reduced because of an increase in methaemoglobin ( ^ 5%). In 10 patients the dose was lowered to 50 mg because of a reduction of haemoglobin of more than 1 • 6 g% in 2 weeks. Liver and renal function tests remained normal during treatment. Three patients complained of short ness of breath, and two had headache. One patient had a sleep disorder, another had nausea, and fatigue was reported by three patients. In addition to the cutaneous side-effects, sleep disturbance proved to be a significant problem during topical immunotherapy.
Discussion
lasting AA with dapsone is less successful than topical immunotherapy (Fisher's exact test: P < 0 006). As the present investigation was not a placebo-controlled study, the response to dapsone has to be interpreted in the light of the spontaneous recovery rate in alopecia areata. 15 of hair during dapsone therapy were treated with a low dose (50 mg daily), and did not relapse following discontinuation of dapsone. Hence, spontaneous recov ery could be the explanation for the favourable course in both patients. Dapsone has potent anti-inflammatory actions, and is an effective treatment for dermatitis herpetiformis, pustular dermatoses and vasculitis. It interferes with the chemotaxis of polymorphonuclear leucocytes and the respiratory burst of these cells. 26 There is little infor mation about the effect of dapsone on T-cell function. It has been demonstrated by Wozel that phytohaemagglutinin-induced T-cell transformation is inhibited by dapsone.27 However, T cell-mediated diseases show a poor response to dapsone therapy. The negative results of dapsone therapy in AA lend support to the supposition that AA is a T-cell-mediated disease.
In conclusion, the results of the present study do not provide any justification for the treatment of AA with dapsone, as its efficacy remains doubtful and Its sideeffects may be troublesome.
